Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 49 - Preparations for testing in vivo
Patents for A61K 49 - Preparations for testing in vivo (35,376)
05/2003
05/20/2003US6566368 Aministering apomorphine or a pharmaceutically acceptable acid addition salt thereof intranasally and in an amount sufficient to induce an erection adequate for vaginal penetration but less than the amount that induces substantial nausea
05/20/2003US6566082 T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions
05/20/2003US6565885 Methods of spray drying pharmaceutical compositions
05/20/2003US6565830 DTPA monoamides, pharmaceutical agents containing these compounds, their use and process for their production
05/20/2003CA2273140C Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media
05/15/2003WO2003040317A2 Lung cancer therapeutics and diagnostics
05/15/2003WO2003039601A1 Methods for vascular imaging using nanoparticulate contrast agents
05/15/2003WO2003039564A1 Selective targeting of apoptotic cells
05/15/2003WO2003039449A2 Modulation of dopaminergic neurons
05/15/2003WO2002083926A3 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
05/15/2003US20030092752 Medical diagnosis; complexing with label
05/15/2003US20030091630 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
05/15/2003US20030091508 Accuracy detection of cell differentiation; cancer diagnosis
05/15/2003US20030091507 Antidiabetic agents; side effect reduction
05/15/2003CA2466303A1 Selective targeting of apoptotic cells
05/15/2003CA2465793A1 Methods for vascular imaging using nanoparticulate contrast agents
05/14/2003EP1309718A2 Neutrokine-alpha and neutrokine-alpha splice variant
05/14/2003EP1309356A2 Tissue marking using biocompatible microparticles
05/14/2003EP1019413B1 Metallation of macrocycles with 2,4-dicarbonyl-metal complexes
05/14/2003EP0958382B1 Novel method for testing the differentiation status in pancreatic cells of a mammal
05/14/2003EP0753065B1 Antibodies against e-selectin
05/13/2003US6563016 Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
05/13/2003US6563015 Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
05/13/2003US6562330 Gelling polyacrylate with pendant zwitterionic groups and counterion component in body cavity; improving biocompatibi-lity; such as embolizing vein or packing aneurysm
05/13/2003US6562320 Thermally stabilized contrast agent
05/13/2003US6562318 Nerve adhesion molecule coupled to active substance; undergoes axonal transport following neuronal endocytosis when contacted with nerve terminus in vascularized innervated tissue
05/13/2003US6562317 For treating solid mass tumors via catheter delivery, comprising a biocompatible polymer, a biocompatible solvent and a water insoluble radioisotope of given radioactive content
05/13/2003CA2203014C Diagnostic preparation for detection of heliobacter pylori
05/08/2003WO2003038396A2 Method for detecting macromolecular conformational change and binding information
05/08/2003WO2003038395A2 Remote nmr/mri detection of laser polarized gases
05/08/2003WO2003038123A2 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
05/08/2003WO2003037902A1 Separation of regioisomers of metal phthalocyanines
05/08/2003WO2003037400A2 Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo
05/08/2003WO2003037298A2 Bowel cleansing agent
05/08/2003WO2003023404A8 A method of diagnosis and treatment and agents useful for same
05/08/2003WO2002094191A3 Detection of alzheimer's amyloid by magnetic resonance imaging
05/08/2003WO2002024226A9 Photosensitisers
05/08/2003WO2001082899A9 Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
05/08/2003US20030088885 Enhanced resolution of tumor metastasis using a skin flap model
05/08/2003US20030088176 Non-invasive methods for surgery in the vasculature
05/08/2003US20030087807 Methods for identifying compounds for motion sickness, vertigo and other disorders related to balance and the perception of gravity
05/08/2003US20030087799 Modulation
05/08/2003US20030087798 Atopy-associated sequence variants on chromosome 12
05/08/2003US20030087420 Transgenic animals and cells expressing proteins necessary for susceptibility to HIV infection
05/08/2003US20030087407 Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
05/08/2003US20030087384 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment fibroblast growth factor receptor defects
05/08/2003US20030087239 Biosensor for use as tool in human diagnostic and therapeutics
05/08/2003US20030087234 Preparation of labeled biopolymers in situ; obtain bacteria, incubate with label and reaction mixture, separate, recover and analyze labeled bacteria
05/08/2003US20030086875 Liposome containing hydrophobic iodine compound and X-ray contrast medium for radiograph comprising the liposome
05/08/2003US20030086874 Kits for embolizing vascular sites
05/08/2003US20030086872 SUT-2 and SUT-3 genes, proteins and assays for inhibitors of lymphocyte adhesion
05/08/2003US20030086871 Exposing eukaryotic organisms to a single fungal pathogen in the presence of at least one candidate compound; identifying a compound that inhibits fungal pathogen in each of eukaryotic organisms
05/08/2003US20030086870 Methods for detecting lesions in dense breast tissue using LHRH antagonists
05/08/2003US20030086869 Obtaining sample of blood from mammal; administering digestible first fatty acid- containing substrate; obtaining sample; assaying; determining from the rate of fatty acid absorption of fatty acid-substrate; comparing
05/08/2003US20030086867 Blood clot-targeted nanoparticles
05/08/2003CA2464995A1 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
05/07/2003EP1308481A2 Metal-mediated cross-coupling with ring-metalated porphyrins
05/07/2003EP1308126A2 Apparatus and method for detecting magnetic fluid
05/07/2003EP1307582A2 Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis
05/07/2003EP1307486A2 Somatostatin analogues
05/07/2003EP1307446A1 Perfluoroalkyl-containing complexes comprising sugar residues, method for producing the same and use thereof
05/07/2003EP1307238A2 Contrast medium for medical diagnostics
05/07/2003EP1307237A2 Complexes containing perfluoroalkyl with polar radicals, method for the production and use thereof
05/07/2003EP1307236A2 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
05/07/2003EP1029039A4 Non-transgenic animal model of alzheimer's disease
05/07/2003EP1019023B1 Stabilized preparations for use in nebulizers
05/07/2003EP0665729B1 Biocompatible polymers containing diagnostic or therapeutic moieties
05/07/2003EP0627940B1 Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
05/07/2003CA2397005A1 Modulation
05/06/2003US6559330 Calcium complex of [[(4r)-4-[bis{carboxy-.kappa.o)methyl]amino-.kappa.n]-6,9-bis[(carboxy.kappa.o)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-ylic-acid-.kappa.n6,.kappa.n9,.kappa.011]1-oxidato(6-)]-, hexahydrogen, its salts, pharmaceutical agents that contain these complexes, their use in treatment and as additives in diagnosis, as well as processes for the production of the complexes and agents
05/06/2003US6559315 Phenyl- and pyridyl-substituted thiazoline acid derivatives useful in diagnosing and treating pathological conditions associated with an excess of trivalent metals in humans and animals.
05/06/2003US6559183 Nano-emulsion of 5-aminolevulinic acid
05/06/2003US6558961 Immunodiagnostics using particle delivery methods
05/06/2003US6558676 Immunizing mammal with noninfectious material and isolating antibodies produced
05/06/2003US6558669 Aminopolycarboxylate appended peptide
05/06/2003US6558649 Vitronectin receptor antagonist pharmaceuticals
05/06/2003CA2260938C Polymer-lipid microencapsulated gases for use as imaging agents
05/06/2003CA2082160C Humanised and chimeric monoclonal antibodies
05/03/2003WO2003022863A1 Secreted and cell surface genes expressed in benign and malignant colorectal tumors
05/02/2003EP1306380A1 Novel expanded porphyrins and process for the synthesis thereof
05/02/2003EP1306095A2 Methods and compositions for targeting the vasculature of solid tumors
05/02/2003EP1305425A2 Drug metabolizing enzymes
05/02/2003EP1305342A2 Human kininogen d5 domain polypeptides and their use
05/02/2003EP1305340A2 Sequences for integrin alpha-8
05/02/2003EP1305317A1 Dihydroporphyrin derivatives and their uses
05/02/2003EP1305029A1 Method of increasing sensitivity of mammography
05/02/2003EP1212103A4 4-fluoroalkyl-3-halophenyl nortropanes
05/02/2003EP0802767B1 Inhalable contrast agent
05/02/2003EP0674710B1 Peptides with broad neoplastic specificity
05/01/2003WO2003036317A2 Optical pumping modules, polarized gas blending and dispensing systems, and automated polarized gas distribution systems
05/01/2003WO2003036316A1 Automated modular hyperpolarizers
05/01/2003WO2003035655A1 Tissue specific fluorescent chelates
05/01/2003WO2003035114A1 Radiopharmaceutical agent for the treatment of early stage cancer
05/01/2003WO2003035113A1 Magnetic nanodispersion comprising cyclodextrines and method for the production thereof
05/01/2003WO2003035069A1 Apomorphine-containing dosage form for ameliorating male erectile dysfunction
05/01/2003WO2003035029A1 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
05/01/2003WO2003034975A2 Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
05/01/2003WO2002094215A3 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
05/01/2003WO2002067850A9 B/b-like fragment targeting for the purposes of photodynamic therapy and medical imaging
05/01/2003WO2002041760A3 Fluorescence-mediated molecular tomography
1 ... 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 ... 354